canertinib has been researched along with docetaxel anhydrous in 2 studies
| Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) | Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) |
|---|---|---|---|---|---|
| 124 | 9 | 65 | 12,110 | 3,216 | 6,920 |
| Protein | Taxonomy | canertinib (IC50) | docetaxel anhydrous (IC50) |
|---|---|---|---|
| Kinesin-like protein KIF11 | Homo sapiens (human) | 0.0014 | |
| Nucleotide-binding oligomerization domain-containing protein 2 | Homo sapiens (human) | 5.0119 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Arun, BK; Eder, JP; Eiseman, IA; Garland, LL; Hidalgo, M; Lenehan, PF; Lovalvo, JL; Mendelson, DS; Olson, SC; Ryan, DP | 1 |
1 trial(s) available for canertinib and docetaxel anhydrous
| Article | Year |
|---|---|
A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Models, Chemical; Morpholines; Neoplasms; Neutropenia; Taxoids | 2006 |
1 other study(ies) available for canertinib and docetaxel anhydrous
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |